SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes

Theodore K Malmstrom, Douglas K Miller, Eleanor M Simonsick, Luigi Ferrucci, John E Morley, Theodore K Malmstrom, Douglas K Miller, Eleanor M Simonsick, Luigi Ferrucci, John E Morley

Abstract

Background: A brief, inexpensive screening test for sarcopenia would be helpful for clinicians and their patients. To screen for persons with sarcopenia, we developed a simple five-item questionnaire (SARC-F) based on cardinal features or consequences of sarcopenia.

Methods: We investigated the utility of SARC-F in the African American Health (AAH) study, Baltimore Longitudinal Study of Aging (BLSA), and National Health and Nutrition Examination Survey (NHANES). Internal consistency reliability for SARC-F was determined using Cronbach's alpha. We evaluated SARC-F factorial validity using principal components analysis and criterion validity by examining its association with exam-based indicators of sarcopenia. Construct validity was examined using cross-sectional and longitudinal differences among those with high (≥4) vs. low (<4) SARC-F scores for mortality and health outcomes.

Results: SARC-F exhibited good internal consistency reliability and factorial, criterion, and construct validity. AAH participants with SARC-F scores ≥ 4 had more Instrumental Activity of Daily Living (IADL) deficits, slower chair stand times, lower grip strength, lower short physical performance battery scores, and a higher likelihood of recent hospitalization and of having a gait speed of <0.8 m/s. SARC-F scores ≥ 4 in AAH also were associated with 6 year IADL deficits, slower chair stand times, lower short physical performance battery scores, having a gait speed of <0.8 m/s, being hospitalized recently, and mortality. SARC-F scores ≥ 4 in the BLSA cohort were associated with having more IADL deficits and lower grip strength (both hands) in cross-sectional comparisons and with IADL deficits, lower grip strength (both hands), and mortality at follow-up. NHANES participants with SARC-F scores ≥ 4 had slower 20 ft walk times, had lower peak force knee extensor strength, and were more likely to have been hospitalized recently in cross-sectional analyses.

Conclusions: The SARC-F proved internally consistent and valid for detecting persons at risk for adverse outcomes from sarcopenia in AAH, BLSA, and NHANES.

Keywords: Function; Mobility; Sarcopenia; Screening.

References

    1. Rolland Y, Czerwinski S, Abellan van Kan G, Morley JE, Cesari M, Onder G, et al Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008; 12: 433–450.
    1. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med 2001; 137: 231–243.
    1. Cruz‐Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412–423.
    1. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc 2011; 12: 249–256.
    1. Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 2011; 12: 403–409.
    1. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength: a qualitative review. Front Physiol 2012; 3: 260.
    1. Manini TM, Clark BC. Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci 2012; 67: 28–40.
    1. Bouchard DR, Janssen I. Dynapenic‐obesity and physical function in older adults. J Gerontol A Biol Sci Med Sci 2010; 65: 71–77.
    1. Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E. BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 2009; 20: 1675–1682.
    1. Leslie WD, Morin S, Lix LM, Johansson H, Oden A, McCloskey E, et al Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 2012; 23: 75–85.
    1. Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2012; 16: 601–608.
    1. Miller DK, Wolinsky FD, Malmstrom TK, Andresen EM, Miller JP. Inner city, middle‐aged African Americans have excess frank and subclinical disability. J Gerontol A Biol Sci Med Sci 2005; 60: 207–212.
    1. Malmstrom TK, Miller DK, Herning MM, Morley JE. Low appendicular skeletal muscle mass (ASM) with limited mobility and poor health outcomes in middle‐aged African Americans. J Cachexia Sarcopenia Muscle 2013; 4: 179–186.
    1. Malmstrom TK, Morley JE. Sarcopenia: the target population. J Frailty Aging 2013; 2: 55–56.
    1. Schrack JA, Simonsick EM, Chaves PH, Ferrucci L. The role of energetic cost in the age‐related slowing of gait speed. J Am Geriatr Soc 2012; 60: 1811–1816.
    1. US Department of Health and Human Services . National Center for Health Statistics In The National Health and Nutrition Examination Survey: Sample Design, 1999–2006. Washington, DC: Centers for Disease Control and Prevention; 2012.
    1. Miller DK, Malmstrom TK, Andresen EM, Miller JP, Herning MM, Schootman M, et al Development and validation of a short portable sarcopenia measure in the African American Health project. J Gerontol A Biol Sci Med Sci 2009; 64A: 388–394.
    1. National Center for Health Statistics . Data File Documentation, National Health Interview Second Supplement on Aging, 1994 (Machine Readable Data File and Documentation). Hyattsville, MD: National Center for Health Statistics; 1998.
    1. Lawton MP, Brody EM. Assessment of older people: self‐maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179–186.
    1. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al A short physical performance battery assessing lower extremity function: association with self‐reported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49: M85–M94.
    1. Miller DK, Wolinsky FD, Andresen EM, Malmstrom TK, Miller JP. Adverse outcomes and correlates of change in the Short Physical Performance Battery over 36 months in the African American Health project. J Gerontol A Biol Sci Med Sci 2008; 63: 487–494.
    1. Singh NA, Quine S, Clemson LM, Williams EJ, Williamson DA, Stavrinos TM, et al Effects of high‐intensity progressive resistance training and targeted multidisciplinary treatment of frailty on mortality and nursing home admissions after hip fracture: a randomized controlled trial. J Am Med Dir Assoc 2012; 13: 24–30.
    1. Malafarina V, Uriz‐Otano F, Iniesta R, Gil‐Guerrero L. Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: a systematic review. J Am Med Dir Assoc 2013; 14: 10–17.
    1. Candow DG, Forbes SC, Little JP, Cornish SM, Pinkoski C, Chilibeck PD. Effect of nutritional interventions and resistance exercise on aging muscle mass and strength. Biogerontology 2012; 13: 345–358.
    1. Montero‐Fernandez N, Serra‐Rexach JA. Role of exercise on sarcopenia in the elderly. Eur J Phys Rehabil Med 2013; 49: 131–143.
    1. Cesari M, Vellas B. Sarcopenia: a novel clinical condition or still a matter for research? J Am Med Dir Assoc 2012; 13: 766–767.
    1. Morley JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE, et al Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc 2010; 11: 391–396.
    1. Morley JE. Anabolic steroids and frailty. J Am Med Dir Assoc 2010; 11: 533–536.
    1. Rolland Y, Onder G, Morley JE, Gillette‐Guyonet S, Abellan van Kan G, Vellas B. Current and future pharmacologic treatment of sarcopenia. Clin Geriatr Med 2011; 27: 423–447.
    1. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD. FRAX (®) with and without bone mineral density. Calcif Tissue Int 2012; 90: 1–13.
    1. Hirsch C, Anderson ML, Newman A, Kop W, Jackson S, Gottdiener J, et al The association of race with frailty: the cardiovascular health study. Ann Epidemiol 2006; 16: 545–553.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi